Individuals with cardiac implantable electronic devices have a higher risk of tricuspid regurgitation. The U.S. FDA recently approved Attruby (acoramidis) for adults with ATTR-CM to reduce cardiovascular death, hospitalization. A case study highlights the importance of avoiding anchoring bias in the diagnosis of cardiac amyloidosis. The diagnosis of AL amyloidosis requires a high index of suspicion to render a prompt diagnosis and appropriate treatment. Mortality rates among inpatients with HF who undergo AF catheter ablation are relatively low. BC survivors undergoing CIED placement have a higher risk of periprocedural complications. There have been dramatic improvements in remote monitoring among both urban and rural patients with CIED. LAAO in elderly patients with atrial fibrillation demonstrates similar efficacy to those seen in younger patients. Remote analysis of cancerous-looking skin growths yields the same level of accuracy as in-person analysis. Dr. Anne Marie Morse talks about parasomnias, and how they affect quality of life in people who have them. A study further supports the efficacy of acoramidis in the treatment of people with ATTR-CM. Dr. Shaun Grannis talks about a large-scale study which showed the robust efficacy of RSV vaccine in older adults. For patients with CIEDs who undergo remote monitoring, routine in-person visits may not be needed. Researchers assessed the safety of rides for patients with cardiac implantable electronic devices. Frailty significantly increases the risk of both in-hospital mortality, and complications in HFrEF patients following CIED. People with amyloidosis have a significantly higher prevalence of atrial fibrillation. An AI model for detecting ATTR-CA yields solid diagnostic results. On average, the readability of patient educational materials on cardiac amyloidosis fails to meet NIH standards. A deep-learning model is able to detect ATTR-CM with robust efficacy. Practical strategies are needed in health centers to ensure patients with ATTRv receive optimal care.